Galera Therapeutics (GRTX) Stock Overview
A biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
GRTX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Galera Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.023 |
| 52 Week High | US$0.06 |
| 52 Week Low | US$0.015 |
| Beta | 1.98 |
| 1 Month Change | 9.52% |
| 3 Month Change | -2.54% |
| 1 Year Change | -56.69% |
| 3 Year Change | -98.63% |
| 5 Year Change | -99.76% |
| Change since IPO | -99.81% |
Recent News & Updates
Recent updates
Galera Therapeutics (NASDAQ:GRTX) Will Have To Spend Its Cash Wisely
Feb 15
Galera Therapeutics (NASDAQ:GRTX) Will Have To Spend Its Cash Wisely
Oct 25Galera Therapeutics appoints chief medical officer
Sep 01Galera down ~8% after phase 1 data for non-small cell lung cancer combination treatment
Jun 29Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky
Jun 15Is Galera Therapeutics Stock A Buy, Sell, Or Hold? Several Catalysts To Watch In 2022
Mar 23Here's Why We're A Bit Worried About Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation
Feb 24Galera Therapeutics: Trial Reversal Did Not Take The Stock Higher
Dec 24Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky
Nov 04Will Galera Therapeutics (NASDAQ:GRTX) Spend Its Cash Wisely?
Aug 05Here's Why We're Watching Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation
Feb 17Shareholder Returns
| GRTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 28.7% | 3.0% | 1.1% |
| 1Y | -56.7% | 2.7% | 16.7% |
Return vs Industry: GRTX underperformed the US Biotechs industry which returned 2.7% over the past year.
Return vs Market: GRTX underperformed the US Market which returned 16.7% over the past year.
Price Volatility
| GRTX volatility | |
|---|---|
| GRTX Average Weekly Movement | 14.7% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GRTX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: GRTX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 3 | J. Sorensen | www.galeratx.com |
Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer. The company’s lead product is tilarginine that is in Phase 1/2 trial of a pan-inhibitor of nitric oxide synthase to treat patients with highly resistant forms of breast cancer, including metaplastic breast cancer (MpBC) and other refractory subsets of triple-negative breast cancer (TNBC). It develops avasopasem manganese, a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy that is in Phase 2a clinical trial.
Galera Therapeutics, Inc. Fundamentals Summary
| GRTX fundamental statistics | |
|---|---|
| Market cap | US$1.21m |
| Earnings (TTM) | -US$13.18m |
| Revenue (TTM) | n/a |
Is GRTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GRTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$13.18m |
| Earnings | -US$13.18m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.17 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -103.9% |
How did GRTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/22 22:29 |
| End of Day Share Price | 2025/10/22 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Galera Therapeutics, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| null null | BTIG |
| Yigal Nochomovitz | Citigroup Inc |